Sagent Pharmaceuticals, Inc. has launched octreotide acetate injection, a somatostatin analogue, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for octreotide acetate injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.